University Children's Hospital Zurich and Children's Research Centre, Zurich, 8032, Switzerland.
Orphanet J Rare Dis. 2012 May 29;7:32. doi: 10.1186/1750-1172-7-32.
Urea cycle disorders (UCDs) are inborn errors of ammonia detoxification/arginine synthesis due to defects affecting the catalysts of the Krebs-Henseleit cycle (five core enzymes, one activating enzyme and one mitochondrial ornithine/citrulline antiporter) with an estimated incidence of 1:8.000. Patients present with hyperammonemia either shortly after birth (~50%) or, later at any age, leading to death or to severe neurological handicap in many survivors. Despite the existence of effective therapy with alternative pathway therapy and liver transplantation, outcomes remain poor. This may be related to underrecognition and delayed diagnosis due to the nonspecific clinical presentation and insufficient awareness of health care professionals because of disease rarity. These guidelines aim at providing a trans-European consensus to: guide practitioners, set standards of care and help awareness campaigns. To achieve these goals, the guidelines were developed using a Delphi methodology, by having professionals on UCDs across seven European countries to gather all the existing evidence, score it according to the SIGN evidence level system and draw a series of statements supported by an associated level of evidence. The guidelines were revised by external specialist consultants, unrelated authorities in the field of UCDs and practicing pediatricians in training. Although the evidence degree did hardly ever exceed level C (evidence from non-analytical studies like case reports and series), it was sufficient to guide practice on both acute and chronic presentations, address diagnosis, management, monitoring, outcomes, and psychosocial and ethical issues. Also, it identified knowledge voids that must be filled by future research. We believe these guidelines will help to: harmonise practice, set common standards and spread good practices with a positive impact on the outcomes of UCD patients.
尿素循环障碍(UCDs)是由于影响克雷布斯-海斯莱特循环(五种核心酶、一种激活酶和一种线粒体鸟氨酸/瓜氨酸反向转运体)催化剂的氨解毒/精氨酸合成的先天性缺陷所致,其估计发病率为 1:8000。患者表现为高氨血症,要么在出生后不久(约 50%),要么在任何年龄,导致许多幸存者死亡或严重神经残疾。尽管存在替代途径治疗和肝移植等有效治疗方法,但结果仍然不佳。这可能与非特异性临床表现和由于疾病罕见导致医疗保健专业人员认识不足有关,从而导致识别不足和诊断延迟。这些指南旨在提供跨欧洲的共识,以:指导从业者,制定护理标准,并帮助提高认识。为了实现这些目标,指南采用德尔菲法制定,让来自七个欧洲国家的 UCD 专业人员收集所有现有证据,根据 SIGN 证据水平系统对其进行评分,并根据相关证据水平提出一系列声明。指南由外部专家顾问、UCD 领域的无关权威人士和接受培训的儿科医生进行修订。尽管证据程度几乎从未超过 C 级(来自非分析性研究的证据,如病例报告和系列),但足以指导急性和慢性表现的实践,解决诊断、管理、监测、结果以及心理社会和伦理问题。此外,它还确定了必须通过未来研究填补的知识空白。我们相信这些指南将有助于:协调实践,制定共同标准,并传播良好实践,对 UCD 患者的结果产生积极影响。